Dasabuvir (sodium)

• UNSPSC Description:

  Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively[1].

• Target Antigen:

  DNA/RNA Synthesis; HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/dasabuvir-sodium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C=CN(C2=CC(C(C)(C)C)=C(OC)C(C3=CC=C4C=C(NS(=O)(C)=O)C=CC4=C3)=C2)C(N1)=O.[Na]

• Molecular Weight:

  516.56

• References & Citations:

  [1]Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  1132940-11-4